Given claims like "I have 70m doses that I can’t ship because they have been purchased but not approved. They have a shelf life of six months; these expire in April." from https://www.theguardian.com/global-development/2021/feb/14/w... it seems like claiming that the bottleneck is production needs some serious caveats....
Unfortunately, the article doesn't make clear which exact vaccines it's discussing.
So it's entirely possible that the specific vaccines approved in Europe are supply-constrained, while other vaccines are in the situation described in the article. All that means is that saying that "the problem problem is production" is very specific-vaccine and specific-regulatory-unit dependent and needs to be evaluated carefully.
It's only a zero-sum game if more money wouldn't ramp the production up faster. This might be case but I whish people who say it's zero-sum would say why they think so.
Because nobody credible in the vaccine industry is saying "we could speed up XYZ if we had a bit more money." If they did, they'd find themselves buried under an avalanche of cash before they finished the sentence.
The story right now is one of the entire industry ramping up production as fast as they possibly can with money being no object.
Sure, Israel did a great job negotiating for vaccines, but it's a zero-sum game so only a few countries could have pulled this off.